Significant clinical trial and pre-clinical experience exists in the Division of Cardiothoracic Surgery at Stony Brook, suitable to the execution of stem cell trials. Dr. Rosengart and his research group share prolonged experience including the conduct of pre-clinical stem cell research and the design, (PDA) regulatory approval and completion of multi-center, collaborative studies. This experience includes Dr. Rosengart's participation in the design of an industry-sponsored study examining the use of skeletal myoblast implantation in open heart surgery patients ("MAGIC", Genzyme), and his oversight of cell therapy studies as part of the NIH -SCCOR in Cardiac Dysfunction DSMB. Dr. Rosengart's pre-clinical work includes his group's use of angiogenic "pre-treatment" of infarcted tissues to improve the survival and functionality of subsequently implanted stem cells.
Retuerto MA, Beckmann JT, Carbray J, Patejunas G, Sarateanu S, Kane BJ, Smulevitz B, McPherson DD, Rosengart TK. Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts. J Thorac Cardiovasc Surg. 2007 Feb;133(2):478-484.e2.
Nayak L, Rosengart TK. Gene therapy for heart failure. Semin Thorac Cardiovasc Surg. 2005 Winter;17(4):343-7. Review.